A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.

A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.

Inoyama, Daigo;Awasthi, Divya;Capodagli, Glenn C;Tsotetsi, Kholiswa;Sukheja, Paridhi;Zimmerman, Matthew;Li, Shao-Gang;Jadhav, Ravindra;Russo, Riccardo;Wang, Xin;Grady, Courtney;Richmann, Todd;Shrestha, Riju;Li, Liping;Ahn, Yong-Mo;Ho Liang, Hsin Pin;Mina, Marizel;Park, Steven;Perlin, David S;Connell, Nancy;Dartois, Véronique;Alland, David;Neiditch, Matthew B;Kumar, Pradeep;Freundlich, Joel S;
cell chemical biology 2020
262
inoyama2020acell

Abstract

Published Mycobacterium tuberculosis β-ketoacyl-ACP synthase KasA inhibitors lack sufficient potency and/or pharmacokinetic properties. A structure-based approach was used to optimize existing KasA inhibitor DG167. This afforded indazole JSF-3285 with a 30-fold increase in mouse plasma exposure. Biochemical, genetic, and X-ray studies confirmed JSF-3285 targets KasA. JSF-3285 offers substantial activity in an acute mouse model of infection and in the corresponding chronic infection model, with efficacious reductions in colony-forming units at doses as low as 5 mg/kg once daily orally and improvement of the efficacy of front-line drugs isoniazid or rifampicin. JSF-3285 is a promising preclinical candidate for tuberculosis.

Citation

ID: 100929
Ref Key: inoyama2020acell
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
100929
Unique Identifier:
S2451-9456(20)30071-4
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet